Document is current
Any future updates will be listed below
-
Authors
Fowler, Daniel K.
Savage, Tylor M.
Mackie, Duncan I.
-
Funding
Funding for this research was provided by:
Institute of Cannabis Research
- License Information
-
More Information
Article History
Received: 13 February 2026
Accepted: 30 April 2026
First Online: 13 May 2026
Declarations
:
: Not applicable.
: Not applicable.
: DKF, TMS, and DIM were employees of MedPharm Holdings LLC (dba Bud & Mary’s) during the study period. DIM is a Schedule I U.S. Drug Enforcement Administration (DEA) license holder and MedPharm Holdings is a State of Colorado licensed cannabis research company and a bulk manufacturer of cannabis products for the Colorado adult-use marketplace. MedPharm Holdings has no stake in any products tested in studies reviewed by this manuscript. DIM has received research funding from Kemin Industries. DKF is a former employee of Ebbu LLC, and Canopy Growth Corporation. DKF is author of, but does not hold financial interest in patent applications by Canopy Growth Corporation related to cannabis plants with increased cannabigerolic acid (US20230265444A1, US20240102034A1, CA3150867A1) and increased cannabichromenic acid (US20230413750A1, CA3195455A1). DIM is an Editor for Journal of Cannabis Research. DIM was not involved in the journal’s review of, or decisions related to this manuscript.
